The global regulatory climate around cannabis use is evolving and has resulted in a huge investment opportunity for investors seeking to capitalize on this emerging market. A significant player in the global cannabis market, Melodiol Global Health’s (ASX:ME1, FRA:1X8) value proposition is founded on its strategic operations in both Canada and Australia.
In recent years, countries like Canada and Australia have established new regulations to legalize cannabis use, either for recreational or medical purposes – or both. Other countries and regions are not far behind in their cannabis regulation journey.
Melodiol oversees multiple global business units that provide everything from recreational and medical cannabis to hemp-based, athletic, beauty and personal care products. Through subsidiary Halucenex Life Sciences, the company has also dipped its toes into the medical psychedelics market.
Melodiol's two most significant subsidiaries, by far, are Mernova and Health House International. The former is a licensed Canadian producer of small-batch, high-quality craft cannabis with incredibly strong revenue growth. The former is a leading distributor of medical cannabis in Australia with additional non-cannabis operations in the United Kingdom.
The company aims to increase shareholder value and spur further growth in its subsidiaries through optimisation which will ultimately result in improved operating and financial performance. Group revenues for the first half of 2023 totalled AU$6.99 million, representing a 62-percent increase from the same period in 2022 at AU$4.32 million.
Accounting for the recent acquisition of Health House International, unaudited pro forma revenue increased to AU$8.26 million or AU$33 million on an annualised basis — a 280-percent increase from the company's 2022 revenue. Unaudited net sales for the combined Melodiol group in Q2 2023 totaled $4.74 million, a 105-percent gain on the previous quarter and a 202-percent increase on the previous corresponding period. The company has also demonstrated a strong growth trajectory into Q3 2023.
Mernova product suite
Based in Canada, Mernova is a 100-percent-owned subsidiary of Melodiol. As a fully licensed cannabis producer, Mernova produces high-quality craft cannabis intended primarily for recreational use. Its products are among the most concentrated in the Canadian market, with THC content typically 25 percent or higher.
Mernova’s cannabis products are currently available in Saskatchewan, Ontario, Nova Scotia, New Brunswick, Manitoba, Yukon and Newfoundland. Mernova is notable as the first of Melodiol's divisions to generate positive cash flow from operations, achieving significant revenue growth in the first half of 2023. The company currently aims to bring its Mernova products to other markets within Canada and has recently launched a medicinal cannabis division.
A leading distributor of medical cannabis products to the Australian market, Health House International also operates a division in the United Kingdom which distributes medicines and medicinal supplies. The business unit is primed to capitalise on any changes which might occur in the European regulatory climate. Melodiol acquired Health House International in the first quarter of 2023, resulting in a material increase in group revenues.
The company and its operating subsidiaries have delivered strong revenue and positive EBITDA margins throughout the first half of 2023. This trend is expected to continue for the remainder of the year.
ImpACTIVE is a hemp-based athletics brand that provides CBD products to help athletes improve and redefine their recovery routines. In September 2023, the company secured a landmark sponsorship deal with Texas Christian University's highly reputed NCAA Division 1 sports program. The school's large athletics department boasts more than 200,000 social media followers alongside a large and loyal domestic fanbase.
Other ImpACTIVE brand ambassadors include Kevin Tansey, Mark Fraser, Matthew Barnaby, Nathaniel Behar, Colten Saucerman, Kelly Whaley, Will Wilcox and Troy Van Biezen.
Sierra Sage Herbs' primary offering is Green Goo, a branded line of plant-based first aid, beauty and personal care products. The company also maintains two other wholly owned brands, Southern Butter and Good Goo. In addition to a significant direct-to-consumer sales channel, Sierra Sage's distribution network includes key retail outlets across the United States, including Walmart, Walgreens, Target, Albertson and Whole Foods.
A clinical-stage psychedelic drug development company, Halucenex maintains a 6,000-square-foot Canadian medical facility with six treatment rooms and a secure laboratory dedicated to clinical research and psychedelics-assisted psychotherapy. The company has a Health Canada Controlled Drug and Substance Dealer's License for the possession, production, assembly, sale, provisioning, sending, transportation and delivery of multiple compounds including ketamine, psilocin, psilocybin and salvia divinorum.
Its phase 2 clinical trial test on the efficacy of psilocybin in the treatment of post-traumatic stress disorder (PTSD) has delivered promising results thus far, with the first 10 percent of trial patients experiencing total remission from both depression and PTSD symptoms after their first macro-dose.
Creso Pharma Switzerland is a hemp-based food, feed supplements and topical products brand based in Europe. Backed by an experienced international team from the pharmaceutical industry, it serves the European Union, Switzerland, Eastern Europe, Latin America and Asia Pacific regions. The company's products are all Swiss-made, produced in GMP-certified facilities, as required, and made from EU-certified, GAP-compliant plants.
William Lay is a former investment banker who was involved in more than $5 billion worth of merger and acquisition deals in his role as an associate director at Canadian licenced producer Canopy Growth.
A leading medical cannabis expert, Boaz Wachtel is co-founder and former MD of Phytotech Medical, Australia's first publicly-traded medicinal cannabis company.
Bruce Linton is the co-founder and former chairman of Canopy Growth, a world leader in cannabis and psychedelics.
Micheline MacKay serves as managing director at Mernova, one of Melodiol's key business units. She has 22 years of experience in regulatory environments.
Based in Australia, Ben Quirin has over 20 years of experience in the global telecommunications, technology and pharmaceutical sectors. Prior to his role at Melodiol, Quirin served as regional managing director (APAC) for Canopy Growth.
Jodi Scott is co-founder and CEO of Sierra Sage Herbs, Melodiol's US-based subsidiary.
Peter Hatfull has over 40 years of experience in senior executive and board positions with various Australian and international companies.
Chris Grundy is a career CFO with over 30 years of experience in the life sciences sector.
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET.
Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.
The Company's proxy statement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting is available on the Investors section of the Company's website at https://ir.thecronosgroup.com/financial-information/annual-meeting .
Access Information
Date: Thursday, June 20, 2024
Time: 11:00 a.m. ET
Live Audio Webcast Online at: http://www.virtualshareholdermeeting.com/CRON2024
Replay
A replay of the Annual Meeting will be available in the investor relations section of the Company's website ( https://ir.thecronosgroup.com/events-presentations ) starting about 24 hours after the meeting is finished.
About Cronos
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® and Lord Jones ® . For more information about Cronos and its brands, please visit: thecronosgroup.com .
Forward-looking Statements
This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which has been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar , respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
Cronos Group Contact
Shayne Laidlaw
Investor Relations
Tel: (416) 504-0004
investor.relations@thecronosgroup.com
News Provided by GlobeNewswire via QuoteMedia
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.
To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations . To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.
About Cronos
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® and Lord Jones ® . For more information about Cronos and its brands, please visit: thecronosgroup.com .
Forward-looking Statements
This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 which has been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
Cronos Contact
Shayne Laidlaw
Investor Relations
Tel: (416) 504-0004
investor.relations@thecronosgroup.com
News Provided by GlobeNewswire via QuoteMedia
FinancialBuzz.com News Commentary
Over the past decade, the cannabis market has undergone significant expansion, driven largely by a wave of legalization efforts across the United States and other parts of the world. As state and national governments reassess their legal stance on cannabis, both for medical and recreational use, the industry has seen a surge in legitimacy and economic interest. In the United States, a majority of states have legalized cannabis in some form, reflecting a shift in public opinion and an acknowledgement of the potential medical benefits and revenue generation opportunities. Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth. The financial implications of these legalization efforts are substantial and continue to evolve. According to a report by Grand View Research, the global legal cannabis market size was valued at USD 13.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 25.5% from 2022 to 2030. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), Cronos Group Inc. (NASDAQ: CRON), Canopy Growth Corporation (NASDAQ: CGC), Aurora Cannabis Inc. (NASDAQ: ACB), Curaleaf Holdings, Inc. (OTC: CURLF)
While the cannabis market demonstrates significant economic promise and potential for growth, concerns persist regarding its broader societal impacts, particularly in relation to public safety and health. One of the primary concerns is the correlation between cannabis use and impaired driving. Studies have shown that cannabis can significantly impair motor coordination, reaction times, and decision making, which are critical skills for safe driving. With the increase in cannabis accessibility and consumption following legalization, there is an urgent need for effective measures to mitigate these risks. This includes developing reliable roadside testing for cannabis impairment, public education campaigns to raise awareness about the dangers of driving under the influence, and clear legal frameworks to handle such offenses effectively.
Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), a developer of marijuana breathalyzer devices for law enforcement and the workplace just announced that, "it will be presenting at the International Association for Chemical Testing (IACT) conference in April. Cannabix's Dr. Bruce Goldberger Ph.D., will be presenting on Science & Technology Behind Cannabis Breath Testing and the Company's marijuana breathalyzer system at the conference workshop session. IACT is composed of governmental agency personnel involved in chemical testing related to traffic safety. IACT members are scientific and criminal justice professionals, including forensic scientists, regulatory inspectors, and law enforcement personnel with representatives from a majority of states and international members. IACT has standing committees to address various areas including legislation, training, new equipment and procedures and manufacturers of breath testing equipment.
The Cannabis Breath Testing workshop at IACT 2024 is designed to provide background information regarding the pharmacokinetics and pharmacodynamics of cannabinoids in breath, present the current technology for collection devices from commercial vendors, and discuss the necessary laboratory workflows and analytical considerations when testing these samples.
Dr. Bruce Goldberger is a professor and the former Chief of the Forensic Medicine Division in the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida. Dr. Goldberger served as Director of the University of Florida forensic toxicology laboratory for 30 years. Dr. Goldberger is the Principal Investigator of the Florida Drug-Related Outcomes Surveillance and Tracking System and Co-investigator of the National Drug Early Warning System. Dr. Goldberger is a consultant for the Centers for Disease Control and Prevention's National Center for Injury Prevention and Control, Overdose Mortality Team, and the National Center for Health Statistics, Division of Vital Statistics. Dr. Goldberger is a consultant and senior advisor to Cannabix Technologies Inc."
Cronos Group Inc. (NASDAQ: CRON) reported recently its first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions™ feature a dynamic, multi-texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. "We are thrilled to bolster the recent successful launch of the Lord Jones® brand in Canada with our first chocolate edibles," said Jeff Jacobson, Chief Growth Officer, Cronos. "These hand-crafted and artfully created chocolates demonstrate our passion for delivering a differentiated experience through an innovative cannabis product that our consumers will love. This breakthrough innovation is the result of our continuous commitment to and investment in R&D and product development, and we're excited to add Chocolate Fusions™ to our growing family of premium and THC-focused Lord Jones® products in Canada, which are designed to take adult consumers above and beyond."
Canopy Growth Corporation (NASDAQ: CGC) announced earlier in February the introduction of five new pre-roll products across the Company's adult-use cannabis portfolio from brands 7ACRES and Hiway. "Forging ahead with our commitment to innovation, we're excited to offer new pre-roll offerings that meet consumers across a range of occasions and price points," said Dave Paterson, President, Canada, Canopy Growth. "With convenience and enjoyment in mind, our new 7ACRES Smooth Burners offer a high-quality pre-roll with a unique filter design enabling a smooth and slow session, while our new Hiway Water Hash Infused pre-rolls provide consumers a premium experience in a value package."
Aurora Cannabis Inc. (NASDAQ: ACB) together with subsidiary company, MedReleaf Australia, have announced last month the availability of medical cannabis pastilles for doctors to prescribe to patients in Australia. The novel product is produced by Aurora and distributed by MedReleaf Australia, a leading distributor of medical cannabis products with the number two position in the Australian market. "Australia is the largest nationally legal medical market globally, and as a long-standing supplier to MedReleaf Australia and recently announced parent company, we're eager to support the continued growth and development of the market," said Andre Jerome, Executive Vice President of Global Business Development, Aurora. "The introduction of innovative and differentiated products, such as pastilles, and planned upcoming innovation, will provide Australian doctors expanded options for patient care and enhance patient access to the premium medical cannabis they seek," continued Jerome.
Curaleaf Holdings, Inc. (OTCQX: CURLF) announced last month it has signed a deal to acquire Northern Green Canada ("NGC"), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets. NGC is one of the few Canadian cultivators with EU-GMP certification. As such, NGC has consistently supplied high THC, non-irradiated flower to the German market, which is expected to see exponential growth following the recent removal of cannabis from the narcotics list. NGC is also increasingly supplying Australia and New Zealand, the world's fastest-growing cannabis markets.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For cannabix technologies inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com
info@financialbuzz.com
+1-877-601-1879
www.FinancialBuzz.com
SOURCE FinancialBuzz.com
News Provided by GlobeNewswire via QuoteMedia
New location on U.S. Highway 1 will host grand opening celebration Friday
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in North Palm Beach, Florida .
A grand opening celebration will be held Friday, April 26 , beginning at 9 a.m. , featuring music, specials, discounts, and opportunities to register for upcoming patient education sessions.
"We are thrilled to expand access to medical cannabis in Florida with this new dispensary," said Trulieve's Chief Executive Officer Kim Rivers . "Patients in Palm Beach County can find their favorite top-quality branded cannabis products and experience Trulieve's world-class customer service at this convenient location."
The new dispensary, located at 11859 U.S. Hwy 1, will be open 9 a.m. – 8:30 p.m. Monday through Saturday and 11 a.m. – 8 p.m. on Sundays , offering walk-in and express pickup service.
Trulieve North Palm Beach will carry a wide variety of popular products including Trulieve's portfolio of in-house brands such as Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One, Sweet Talk, and Trekkers. Customers will also have access to beloved partner brands such as Alien Labs, Bellamy Brothers , Binske, Black Tuna, Blue River , Connected Cannabis, DeLisioso, Khalifa Kush , Love's Oven, Miami Mango, O.pen, Seed Junky, and Sunshine Cannabis, all available exclusively at Trulieve in Florida .
Across Florida , Trulieve offers home delivery, convenient online ordering, and in-store pickup. Veterans receive 20% off every order when they show their military ID, and all first-time guests are eligible for a 60% new customer discount at any Florida Trulieve location. For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Instagram or Facebook .
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve_
X: @Trulieve
Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-to-open-medical-cannabis-dispensary-in-north-palm-beach-florida-302122904.html
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/22/c0872.html
News Provided by Canada Newswire via QuoteMedia
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Thursday, May 9, 2024 at 8:30 AM Eastern Time following the release of its first quarter 2024 financial results.
Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.
Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.
North American toll free: 1-844-824-3830 | Passcode: | 3368806 |
International: 1-412-542-4136 | Passcode: | 3368806 |
A live audio webcast of the conference call will be available at:
https://app.webinar.net/gl7Pnd4n40e
An archived replay of the webcast will be available at:
https://investors.trulieve.com/events
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve
Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-first-quarter-2024-results-conference-call-on-may-9-2024-302108647.html
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/05/c4744.html
News Provided by Canada Newswire via QuoteMedia